What is Claimed:

1. Use of ~~an effective amount of at least one PLA2 inhibitor and/or at least one metalloprotease inhibitor alone or in combination with at least one antibiotic in the manufacture of medicament for reducing the likelihood that an injured patient or subject at risk of an inflammatory syndrome that will produce one or more of sepsis, septic shock, and acute inflammatory syndrome whether iatrogenic or not or acute respiratory distress syndrome~~ at least one PLA2 inhibitor and/or metalloprotease inhibitor in the manufacture of a medicament for use in a method of reducing the likelihood that an injured patient or subject at risk of an inflammatory syndrome will produce one or more of sepsis, septic shock, an acute inflammatory syndrome (whether iatrogenic or not) or acute respiratory distress syndrome, wherein the method comprises administering the medicament alone or in combination with at least one antibiotic to the patient or subject.

2. The use according to claim 1, wherein said medicament is combined with or administered with at least one antibiotic~~according to claim 1 wherein said PLA2 inhibitor is varespladib (LY315920), methyl varespladib (LY333013), AZD2716- as the racemic mixture or enantiomer thereof, AZD Compound 4, LY433771 ((9-[(phenyl)methyl]-5-carbamoylcarbazol-4-yl)oxyacetic acid), a pharmaceutically acceptable salt thereof or a mixture thereof~~.

3. ~~The u~~Use ~~according to claim 1 or 2 wherein said metalloprotease inhibitor is prinomastat, BB-94 (marimastat), BB-2516 (batimastat), vorinostat, cefixime and doxycycline, a pharmaceutically acceptable salt thereof or a mixture thereof~~ of at least one PLA2 inhibitor and/or metalloprotease inhibitor in the manufacture of a medicament for use in a method of treating an injured or burned patient or subject to improve wound healing of injured and/or burned tissue and/or to inhibit, ameliorate or reduce the likelihood of one or more of sepsis, septic shock, acute inflammatory syndrome, including inflammatory response syndrome (SIRS) and/or acute respiratory distress syndrome (ARDS) in said patient or subject, wherein the method comprises administering the medicament in combination with at least one antibiotic to the patient or subject.

4. ~~The u~~Use ~~according to any of claims 1-3 wherein said PLA2 inhibitor and/or said metalloprotease inhibitor is combined with at least one antibiotic~~ of at least one PLA2 inhibitor and/or metalloprotease inhibitor in the manufacture of a medicament for use in a method of treating a patient or subject with sepsis, including early sepsis, wherein the method comprises administering the medicament in combination with at least one antibiotic to the patient or subject.

5. ~~The u~~Use ~~according to claim 4 wherein said antibiotic is selected from the group consisting of a penam, a carboxylpenicillin, a cephalosporin, a monobactam, a carbapenem, a fluoroqunoline, a macrolide or a mixture thereof~~ of at least one PLA2 inhibitor and/or at least one metalloprotease inhibitor in the manufacture of a medicament for inhibiting or reducing the likelihood of a COVID-19/cytokine release syndrome in a patient at risk of same.

6. Use of ~~an effective amount of at least one PLA2 inhibitor and/or a metalloprotease inhibitor in combination with an effective amount of at least one antibiotic in the manufacture of medicament for treating an injured or burned patient or subject to improve wound healing and/or to inhibit, ameliorate or reduce the likelihood of one or more of sepsis, septic shock, acute inflammatory syndrome in said patient or subject~~ at least one PLA2 inhibitor in the manufacture of a medicament for treating neo-natal acute respiratory distress syndrome (neo-natal ARDS), including meconium aspiration syndrome.

7. ~~The u~~Use according to claim 6, wherein said neo-natal ARDS is meconium aspiration syndrome (MAS)~~wherein the acute inflammatory syndrome is inflammatory response syndrome (SIRS) and/or acute respiratory distress syndrome (ARDS)~~.

8. A~~The use according to claim 6 or 7 comprising the use at least two antibiotics~~ pharmaceutical composition for use in a method of treating a patient at risk for or afflicted with one or more of sepsis, septic shock, acute inflammatory syndrome, including inflammatory response syndrome (SIRS) and/or acute respiratory distress syndrome (ARDS), comprising at least one PLA2 inhibitor and/or at least one metalloprotease inhibitor, wherein the composition further comprises at least one antibiotic or is administered in combination with at least one antibiotic.

9. The use or the pharmaceutical composition according to any one of claims 1-5 and 8, wherein said medicament or pharmaceutical composition comprises at least one PLA2 inhibitor~~according to any one of claims 6-8 wherein said antibiotic(s) is in combination with at least one PLA2 inhibitor~~.

10. The use or the pharmaceutical composition according to any one of claims 1-5 and 8, wherein said medicament or pharmaceutical composition comprises at least one metalloprotease inhibitor~~according to any of claims 6-9 wherein said antibiotic(s) is in combination with at least one metalloprotease inhibitor~~.

11. The use or the pharmaceutical composition according to any one of claims 1-5 and 8, wherein said medicament or pharmaceutical composition comprises at least one PLA2 inhibitor and at least one metalloprotease inhibitor~~according to any of claims 6-10 wherein said PLA2 inhibitor is varespladib (LY315920), methyl varespladib (LY333013), AZD2716 as a racemic mixture or enantiomer thereof, AZD Compound 4, LY433771 ((9~~

~~[(phenyl)methyl]-5-carbamoylcarbazol-4-yl)oxyacetic acid), darapladib, a pharmaceutically acceptable salt thereof or a mixture thereof~~.

12. The use ~~according to any of claims 6-10 wherein said metalloprotease inhibitor is prinomastat, BB-94 (marimastat), BB-2516 (batimastat), vorinostat, cefixime and doxycycline, a pharmace utically acceptable salt thereof or a mixture thereof~~ or the pharmaceutical composition according to any one of claims 1-11, wherein said PLA2 inhibitor is varespladib (LY315920), methyl varespladib (LY333013), AZD2716- as a racemic mixture or enantiomer thereof, AZD Compound 4, LY433771 ((9-[(phenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid), a pharmaceutically acceptable salt thereof or a mixture thereof.

13. The ~~U~~use ~~of an effective amount of at least one antibiotic and an effective amount of at least one PLA2 inhibitor and/or a metalloprotease inhibitor in the manufacture of medicament for treating a patient or subject with sepsis~~or the pharmaceutical composition according to any one of claims 1-5 and 8-12, wherein said metalloprotease inhibitor is prinomastat, BB-94 (marimastat), BB-2516 (batimastat), vorinostat, cefixime and doxycycline, a pharmaceutically acceptable salt thereof or a mixture thereof.

14. The use ~~according to claim 13 wherein the sepsis is early sepsis~~ use or the pharmaceutical composition according to any one of claims 1-4 and 8-13, wherein said antibiotic is selected from the group consisting of a penam, a carboxylpenicillin, a cephalosporin, a monobactam, a carbapenem, a fluoroqunoline, a macrolide or a mixture thereof.

~~15. The use according to claim 13 and 14 comprising at least two antibiotics.~~

~~16. The use according to any one of claims 13-15 wherein said antibiotic(s) is in combination with at least one PLA2 inhibitor.~~

~~17. The use according to any one of claims 13-16 wherein said antibiotic(s) is in combination with at least one metalloprotease inhibitor.~~

~~18. The use according to any of claims 13-16 wherein said PLA2 inhibitor is varespladib (LY315920), methyl varespladib (LY333013), AZD2716- as a racemic mixture or enantiomer thereof, AZD Compound 4, LY433771 ((9-[(phenyl)methyl]-5-carbamoylcarbazol-4-yl)oxyacetic acid), darapladib, a pharmaceutically acceptable salt thereof or a mixture thereof.~~

~~19. The use according to any of claims 13-18 wherein said metalloprotease inhibitor is prinomastat, BB-94 (marimastat), BB-2516 (batimastat), vorinostat, cefixime and doxycycline, a pharmaceutically acceptable salt thereof or a mixture thereof.~~

~~20. A method for preserving a blood sample(s) taken from a patient or subject who has injuries or burns which place the patient or subject at risk for one or more of sepsis, septic shock, acute inflammatory syndrome, the method comprising combining in said blood sample an effective amount of at least one PLA2 inhibitor and/or at least one~~

metalloprotease each alone, together or in combination with an effective amount of at least one antibiotic.

21. The method of claim 20 wherein the acute inflammatory syndrome is inflammatory response syndrome (SIRS) and/or acute respiratory distress syndrome (ARDS).

22. The method according to claim 20 or 21 wherein said blood sample is combined with at least one PLA2 inhibitor.

23. The method according to any one of claims 20-22 wherein said antibiotic(s) is combined with at least one metalloprotease inhibitor.

24. The method according to any one of claims 20-23 wherein said PLA2 inhibitor is varespladib (LY315920), methyl varespladib (LY333013), AZD2716 as a racemic mixture or enantiomer thereof, AZD Compound 4, LY433771 ((9-[(phenyl)methyl]-5-carbamoylcarbazol-4-yl)oxyacetic acid), a pharmaceutically acceptable salt thereof or a mixture thereof.

25. The method according to any one of claims 20-24 wherein said metalloprotease inhibitor is prinomastat, BB-94 (marimastat), BB-2516 (batimastat), vorinostat, cefixime and doxycycline, a pharmaceutically acceptable salt thereof or a mixture thereof.

26. A composition comprising a blood sample(s) taken from a patient or subject who has injuries or burns which place the patient or subject at risk for one or more of sepsis, septic shock, acute inflammatory syndrome,

~~in combination with an effective amount of at least one PLA2 inhibitor and/or at least one metalloprotease each alone, together or in combination with an effective amount of at least one antibiotic.~~

27. The composition of claim 26 wherein the acute inflammatory syndrome is inflammatory response syndrome (SIRS) and/or acute respiratory distress syndrome (ARDS).

28. The composition according to claim 26 or 27 wherein said blood sample is combined with at least one PLA2 inhibitor.

29. The composition according to any one of claims 26-28 wherein said composition comprises at least one antibiotic and at least one metalloprotease inhibitor.

30. The composition according to any one of claims 26-29 wherein said PLA2 inhibitor is varespladib (LY315920), methyl varespladib (LY333013), AZD2716 as a racemic mixture or enantiomer thereof, AZD Compound 4, LY433771 ((9-[(phenyl)methyl]-5-carbamoylcarbazol-4-yl)oxyacetic acid), darapladib a pharmaceutically acceptable salt thereof or a mixture thereof.

31. The composition according to any one of claims 26-30 wherein said metalloprotease inhibitor is prinomastat, BB-94 (marimastat), BB-2516 (batimastat), vorinostat, cefixime and doxycycline, a pharmaceutically acceptable salt thereof or a mixture thereof.

32. A pharmaceutical composition for use in treating a patient at risk for or afflicted with one or more of sepsis, septic shock, acute inflammatory syndrome, including inflammatory response syndrome (SIRS) and/or acute respiratory distress syndrome (ARDS), comprising an effective amount of at least one antibiotic in combination with at least one PLA2 inhibitor and/or at least one metalloprotease inhibitor.

~~33. The composition according to claim 32 wherein the acute inflammatory syndrome is inflammatory response syndrome (SIRS) and/or acute respiratory distress syndrome (ARDS).~~

~~34. The composition according to claim 32 or 33 comprising at least one PLA2 inhibitor.~~

~~35. The composition according to any one of claims 32-34 comprising at least one metalloprotease inhibitor.~~

~~36. The composition according to any of claims 32-35 wherein said PLA2 inhibitor is varespladib (LY315920), methyl varespladib (LY333013), AZD2716 as a racemic mixture or enantiomer thereof, AZD Compound 4, LY433771 ((9-[(phenyl)methyl]-5-carbamoylcarbazol-4-yl)oxyacetic acid), darapladib, a pharmaceutically acceptable salt thereof or a mixture thereof.~~

~~37. The composition according to any of claims 32-36 wherein said metalloprotease inhibitor is prinomastat, BB-94 (marimastat), BB-2516 (batimastat), vorinostat, cefixime and doxycycline, a pharmaceutically acceptable salt thereof or a mixture thereof.~~

~~38. Use of at least one PLA2 inhibitor and/or at least one metalloprotease inhibitor for inhibiting or reducing the likelihood of a COVID-19/cytokine release syndrome in a patient at risk of same.~~

~~39. The use according to claim 38 wherein said PLA2 inhibitor is varespladib (LY315920), methyl varespladib (LY333013), AZD2716 as a racemic mixture or enantiomer thereof, AZD Compound 4, LY433771 ((9-[(phenyl)methyl]-5-carbamoylcarbazol-4-yl)oxyacetic acid), a pharmaceutically acceptable salt thereof or a mixture thereof.~~

~~40. The use according to claim 38 or 39 wherein said metalloprotease inhibitor is prinomastat, BB-94 (marimastat), BB-2516 (batimastat), vorinostat, cefixime and doxycycline, a pharmaceutically acceptable salt thereof or a mixture thereof.~~

~~41. The use according to any one of claims 1-3 wherein said PLA2 inhibitor and/or said metalloprotease inhibitor are combined.~~

~~42. Use of at least one PLA2 inhibitor in the manufacture of medicament for treating neo-natal acute respiratory distress syndrome (neo-natal ARDS), including meconium aspiration syndrome in a patient in need thereof.~~

~~43. The use according to claim 42 wherein said PLA2 inhibitor is LY315920, LY333013, AZD2716, as an enantiomerically enriched species or as a racemic mixture or mixtures thereof.~~

~~44. The use according to either of claims 42 or 43 wherein said neo-natal ARDS is meconium aspiration syndrome (MAS).~~

~~45. Use of an effective amount of at least one PLA2 inhibitor and/or a metalloprotease inhibitor and optionally at least one antibiotic in the manufacture of medicament for treating a patient or subject in need at risk for or afflicted with anthrax or severe acute respiratory syndrome coronavirus infection (SARS or SARS-CoV2), wherein the use provides an unexpected inhibition, amelioration and/or avoidance of sepsis, septic shock or acute inflammatory syndrome.~~

~~46. The use according to claim 45 wherein the acute inflammatory syndrome is inflammatory response syndrome (SIRS) and/or acute respiratory distress syndrome (ARDS).~~

~~47. The use according to claim 45 or 46 comprising at least two antibiotics in combination with said PLA2 inhibitor(s) and/or said metalloprotease inhibitor(s).~~

~~48. The use according to any once of claims 45-47 wherein at least one PLA2 inhibitor is used.~~

~~49. The use according to any one of claims 45-48 wherein at least one metalloprotease inhibitor is used.~~

~~50. The use according to any one of claims 45-49 wherein said PLA2 inhibitor is varespladib (LY315920), methyl varespladib (LY333013), AZD2716 as a racemic mixture or enantiomer thereof, AZD Compound 4 LY433771 ((9-[(phenyl)methyl]-5-carbamoylcarbazol-4-yl)oxyacetic acid), darapladib, a pharmaceutically acceptable salt thereof or a mixture thereof.~~

~~51. The use according to any of claims 45-50 wherein said metalloprotease inhibitor is prinomastat, BB-94 (marimastat), BB-2516 (batimastat), vorinostat, cefixime and doxycycline, a pharmaceutically acceptable salt thereof or a mixture thereof.~~

~~52. The use according to any of claims 1-19 and 38-51 wherein said PLA2 inhibitor and said metalloprotease inhibitor are formulated for co-administration.~~

~~53. The method according to any of claims 20-25 wherein said PLA2 inhibitor and said metalloprotease inhibitor(s) are used together.~~

~~54. The composition according to any of claims 26-37 comprising at least one PLA2 inhibitor and at least one metalloprotease inhibitor.~~

~~55. The use according to any of claims 1-19 and 38-51 wherein said metalloprotease inhibitor is prinomastat.~~

56. The method according to any of claims 20-25 wherein said metalloprotease inhibitor is prinomastat.

57. The composition according to any one of claims 26-37 wherein said PLA2 inhibitor is varespladib, methylvarespladib, AZD2716 (as a racemic mixture or enantiomer thereof), a pharmaceutically acceptable salt thereof or a mixture thereof.

58. The use according to any of claims 1-19 and 33-45 wherein said PLA2 inhibitor is varespladib, methylvarespladib, AZD2716 (as a racemic mixture or as the "R" enantiomer), a pharmaceutically acceptable salt thereof or a mixture thereof.

59. The method according to any of claims 20-25 wherein said PLA2 inhibitor is varespladib, methylvarespladib, AZD2716 (as a racemic mixture or enantiomer thereof, a pharmaceutically acceptable salt thereof or a mixture thereof.

60. The composition according to any one of claims 26-37 wherein said PLA2 inhibitor is varespladib, methylvarespladib, AZD2716 as a racemic mixture or as an enantiomer thereof, a pharmaceutically acceptable salt thereof or a mixture thereof.

61. A pharmaceutical composition comprising a therapeutically effective amount of at least one PLA2 inhibitor, at least one metalloprotease inhibitor or a mixture thereof in combination with an antibiotic.

62. The composition according to claim 61 wherein said antibiotic is a penam, a carboxylpenicillin, a cephalosporin, a monobactam, a carbapenem, a fluoroqunoline, a macrolide or a mixture thereof.

~~63. The composition according to claim 61 wherein said antibiotic is ciprofloxacin, levofloxacin, moxifloxacin, penicillin g, doxycycline, chloramphenicol, ofloxacin or mixtures thereof.~~

~~64. The composition according to any of claims 61-63 wherein said PLA2 inhibitor is varespladib (LY315920), methyl varespladib (LY333013), AZD2716-~~

~~as a racemic mixture or enantiomer thereof, AZD Compound 4, LY433771 ((9-[(phenyl)methyl]-5-carbamoylcarbazol-4-yl)oxyacetic acid), darapladib, a pharmaceutically acceptable salt thereof or a mixture thereof.~~

~~65. The composition according to any of claims 61-64 wherein said metalloprotease inhibitor is prinomastat, BB-94 (marimastat), BB-2516 (batimastat), vorinostat, cefixime and doxycycline, a pharmaceutically acceptable salt thereof or a mixture thereof.~~